88778 Federal Register / Vol. 89, No. 217 / Friday, November 8, 2024 / Notices 

Procedures Review Finalization/ 

Document Approvals; Savannah River 

Site Workgroup update, Lawrence 

Livermore National Lab Addendum, and 

a Board Work Session. Agenda items are 

subject to change as priorities dictate. 

For additional information, please 

contact Toll Free 1–800–232–4636. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–26007 Filed 11–7–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–25–24FI] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled 

‘‘Comprehensive Evaluations for the 

Well-Integrated Screening and 

Evaluation for Women Across the 

Nation Program (WISEWOMAN), The 

National Cardiovascular Health Program 

(The National CVH Program), and The 

Innovative Cardiovascular Health 

Program (The Innovative CVH 

Program)’’ to the Office of Management 

and Budget (OMB) for review and 

approval. CDC previously published a 

‘‘Proposed Data Collection Submitted 

for Public Comment and 

Recommendations’’ notice on 5/7/2024 

to obtain comments from the public and 

affected agencies. CDC did not receive 

comments related to the previous 

notice. This notice serves to allow an 

additional 30 days for public and 

affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Comprehensive Evaluations for the 

Well-Integrated Screening and 

Evaluation for Women Across the 

Nation Program (WISEWOMAN), The 

National Cardiovascular Health Program 

(The National CVH Program), and The 

Innovative Cardiovascular Health 

Program (The Innovative CVH 

Program)—New—National Center for 

Chronic Disease Prevention and Health 

Promotion (NCCDPHP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC) Division for Heart 

Disease and Stroke Prevention (DHDSP) 

are submitting this new three-year 

information collection request (ICR) for 

an evaluation of the three recently 

launched cooperative agreements: WellIntegrated Screening of Women Across 

the Nation (WISEWOMAN), The 

National Cardiovascular Health Program 

(The National CVH Program), and The 

Innovative Cardiovascular Health 

Program (The Innovative CVH Program). 

The WISEWOMAN program supports 

the early detection and treatment of 

hypertension in low-income, uninsured, 

and underinsured participants, ages 35– 

64. The National CVH Program 

implements evidence-based strategies to 

manage CVD in populations impacted 

by the high prevalence of CVD, 

exacerbated by health inequities and 

disparities, social determinants, such as 

low incomes, poor health care, and 

unfair opportunity structures, 

emphasizing hypertension and high 

cholesterol control among adults aged 

18–85. The Innovative CVH Program 

focuses on implementing innovative 

evidence-based strategies assess and 

address the disparities and inequities in 

communities at highest risk, where 

there is a particular need for equityfocused health system interventions to 

prevent, detect, control, and manage 

hypertension and high cholesterol, 

specifically among populations with a 

crude hypertension prevalence rate of 

53% or higher at the census tract level. 

For two of the cooperative agreements, 

recipients collaborate with public health 

entities, health systems, health care 

providers, community leaders, and 

other partners through Learning 

Collaboratives to facilitate sustainable 

change and improvement in 

cardiovascular health outcomes, 

particularly for those at the highest risk 

of poorer health outcomes. These 

cooperative agreements build upon 

CDC’s previous work of identify 

promising CVD prevention and 

management practices and funding 

various organizations, including State 

and County governments, American 

Indian or Alaska Native tribal 

governments, non-government 

organizations, institutions of higher 

education, to implement evidence-based 

strategies in their jurisdictions. Since 

the cooperative agreements are a 

substantial investment of federal funds, 

it is important to demonstrate the types 

of interventions being implemented and 

what is being accomplished using these 

funds through a comprehensive 

evaluation. 

The comprehensive evaluation of 

these programs includes process and 

outcome evaluations, and a crossprogram analysis to assess the unique 

contributions of each program towards 

evidence-based strategies, health equity 

advancement, and health system 

transformation over the five program 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 217 / Friday, November 8, 2024 / Notices 88779 

years. The evaluation aims to describe 

the implementation of the programs, 

assess the extent to which short-term, 

intermediate, and long-term outcomes 

have been met, and estimate the costs 

involved in implementing the programs. 

The comprehensive evaluation is 

designed to complement the evaluations 

already being conducted by program 

recipients. The data collection focuses 

on obtaining qualitative and cost 

information at the organizational and 

community levels about strategy 

implementation, facilitators and 

barriers, and other contextual 

information that affects program 

implementation and participant 

outcomes. Data collection activities of 

the comprehensive evaluation include 

qualitative interviews for evaluability 

assessments, exploratory assessments, 

and cost data collected for a cost study. 

During the qualitative data collection, 

semi-structured interviews will be 

conducted with recipients, their 

partnering sites, and Learning 

Collaborative members, providing a 

multifaceted view of the program’s 

implementation and outcomes. Cost 

data will be used to estimate the 

implementation costs and value of 

resources invested by program 

recipients and their partners. Cost data 

will be collected through an excel-based 

cost inventory tool, key informant 

interviews, and document reviews. 

There are no costs to respondents except 

their time. Data collection tools are 

crafted to ensure relevance and to 

capture essential information needed to 

evaluate the effectiveness and impact of 

the program strategies, while 

minimizing respondent burden. 

The findings from the data collection 

will provide tailored, action-oriented, 

and timely recommendations for 

program improvement throughout the 

program period. It will foster 

documentation and sharing of lessons 

learned, contribute to the evidence base, 

and support replication and scaling of 

promising program strategies. Without 

collection of evaluative data, CDC will 

not be able to capture critical 

information needed to continuously 

improve programmatic efforts and 

clearly demonstrate the use of federal 

funds. CDC requests OMB approval for 

484 annual burden hours. There is no 

cost to respondents other than their time 

to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Recipients ............................... Evaluability Assessment Nomination Form_NCHP_ICHP ...... 24 1 0.5 

Evaluability Assessment Nomination Form_WW .................... 12 1 0.5 

Eval Assessment CQM Recipient Interview Guide 

NCHP_ICHP.

6 1 1.5 

Eval Assessment CQM Recipient Interview Guide WW ........ 3 1 1.5 

Eval Assessment TBC Recipient Interview Guide 

NCHP_ICHP.

6 1 1.5 

Eval Assessment TBC Recipient Interview Guide WW ......... 3 1 1.5 

Eval Assessment CCL Recipient Interview Guide 

NCHP_ICHP.

3 1 1.5 

Eval Assessment CCL Recipient Interview Guide WW ......... 3 1 1.5 

Ex Assessment CQM Recipient Interview Guide 

NCHP_ICHP.

3 1 1.5 

Ex Assessment CQM Recipient Interview Guide_WW .......... 2 1 1.5 

Ex Assessment TBC Recipient Interview Guide NCHP_ICHP 3 1 1.5 

Ex Assessment TBC Recipient Partner Interview Guide_WW 2 1 1.5 

Ex Assessment CCL Recipient Interview Guide NCHP_ICHP 3 1 1.5 

Ex Assessment CCL Recipient Interview Guide_WW ............ 2 1 1.5 

Cost Study Interview Guide_Recipient ................................... 37 1 1 

Comprehensive Evaluation Resource Use and Cost Inventory Tool_Recipient.37 1 2.5 

Partners .................................. Eval Assessment CQM Partner Interview Guide 

NCHP_ICHP.

6 1 1.5 

Eval Assessment CQM Partner Interview Guide WW ........... 3 1 1.5 

Eval Assessment TBC Partner Interview Guide NCHP_ICHP 6 1 1.5 

Eval Assessment TBC Partner Interview Guide WW ............. 3 1 1.5 

Eval Assessment CCL Partner Interview Guide NCHP_ICHP 6 1 1.5 

Eval Assessment CCL Partner Interview Guide WW ............. 3 1 1.5 

Ex Assessment CQM Partner Interview Guide NCHP_ICHP 3 1 1.5 

Ex Assessment CQM Partner Interview Guide_WW .............. 1 1 1.5 

Ex Assessment CCL Partner Interview Guide NCHP_ICHP .. 3 1 1.5 

Ex Assessment CCL Partner Interview Guide_WW ............... 1 1 1.5 

Ex Assessment TBC Partner Interview Guide NCHP_ICHP .. 3 1 1.5 

Ex Assessment TBC Partner Interview Guide_WW ............... 1 1 1.5 

Cost Study Interview Guide_Partner ...................................... 55 1 1 

Comprehensive Evaluation Resource Use and Cost Inventory Tool_Partner.55 1 2.5 

Learning Collaborative ........... Eval Assessment LC Interview Guide NCHP ICHP ............... 12 1 1 

Ex Assessment LC Interview Guide NCHP_ICHP ................. 6 1 1 


ddrumheller on DSK120RN23PROD with NOTICES1
88780 Federal Register / Vol. 89, No. 217 / Friday, November 8, 2024 / Notices 

1 86 FR 7009, January 25, 2021. 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–25986 Filed 11–7–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2024–0072] 

Advisory Committee on Immunization 

Practices; Amended Notice of Meeting 

AGENCY: Centers for Disease Control and 

Prevention, Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces an 

amendment to the following meeting of 

the Advisory Committee on 

Immunization Practices (ACIP). This 

meeting was open to the public. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, Committee 

Management Specialist, Advisory 

Committee on Immunization Practices, 

National Center for Immunization and 

Respiratory Diseases, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–8, 

Atlanta, Georgia 30329–4027. 

Telephone: (404) 639–8836; Email: 

ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given of a change in the meeting 

of the Advisory Committee on 

Immunization Practices (ACIP); October 

23, 2024, from 8 a.m. to 5:30 p.m., EDT, 

and October 24, 2024, from 8 a.m. to 

5:30 p.m., EDT (times subject to change; 

see the ACIP website for updates: 

https://www.cdc.gov/vaccines/acip/ 

index.html), in the original Federal 

Register notice. 

Notice of the virtual meeting was 

published in the Federal Register on 

September 30, 2024, 89 FR 79610– 

79611. 

The meeting notice is being amended 

to update the recommendation votes in 

the matters to be considered, which 

should read as follows: 

Matters to be Considered: The agenda 

will include discussions on 

chikungunya vaccines, COVID–19 

vaccines, cytomegalovirus (CMV) 

vaccine, Human papillomavirus (HPV) 

vaccines, influenza vaccines, 

meningococcal vaccines, mpox 

vaccines, pneumococcal vaccines, 

Respiratory Syncytial Virus (RSV) 

vaccines for adults, RSV vaccines for 

maternal and pediatric populations, and 

the adult and child/adolescent 

immunization schedules. 

Recommendation votes are scheduled 

for COVID–19 vaccines, meningococcal 

vaccines, pneumococcal vaccines, and 

the adult and child/adolescent 

immunization schedules. A Vaccines for 

Children (VFC) vote is scheduled for 

influenza vaccines and meningococcal 

vaccines. For more information on the 

meeting agenda, visit https://

www.cdc.gov/acip/meetings/index.html. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–26000 Filed 11–7–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–5054–N] 

Medicare, Medicaid, Children’s Health 

Insurance Program, Private Health 

Insurance Program; Health Equity 

Advisory Committee; Establishment & 

Nomination Request 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

establishment of the Centers for 

Medicare and Medicaid Services (CMS) 

Health Equity Advisory Committee (the 

‘‘Committee’’) and solicits nominations 

for members to be appointed to the 

Committee by the Director of the CMS 

Office of Minority Health. The 

Committee is established to advise and 

make recommendations to CMS on the 

identification and resolution of systemic 

barriers to accessing CMS programs that 

hinder quality of care for beneficiaries 

and consumers. The Committee will 

focus on health disparities in 

underserved communities, which are 

populations sharing a particular 

characteristic, as well as geographic 

communities, that have been 

systematically denied a full opportunity 

to participate in aspects of economic, 

social, and civic life, such as but not 

limited to Black, Latino, and Indigenous 

and Native American persons, Asian 

Americans and Pacific Islanders and 

other persons of color; members of 

religious minorities; lesbian, gay, 

bisexual, transgender, and queer 

persons; persons with disabilities; 

persons who live in rural areas; and 

persons otherwise adversely affected by 

persistent poverty or inequality as 

defined in the Executive Order, 

Advancing Racial Equity and Support 

for Underserved Communities Through 

the Federal Government. 

DATES: Nominations must be received 

no later than December 12, 2024. 

ADDRESSES: Nominations and requests 

for copies of the Health Equity Advisory 

Committee (HEAC) Charter may be 

submitted to the address specified 

below. Please do not submit duplicates. 

Nominations or requests for copies of 

the HEAC Charter must be submitted by 

email to HEAC@cms.hhs.gov with the 

subject line ‘‘HEAC Nomination’’ or 

‘‘HEAC Request for Charter,’’ depending 

on the content of the email. 

FOR FURTHER INFORMATION CONTACT: Iris 

Allen, Centers for Medicare & Medicaid 

Services, HHS, at (410) 786–1633. 

Press inquiries may be submitted by 

phone at (202) 690–6145 or by email 

press@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

The Health Equity Advisory 

Committee (the ‘‘Committee’’ or 

‘‘HEAC’’) is established to advise and 

make recommendations to the Centers 

for Medicare & Medicaid Services (CMS) 

on the identification and resolution of 

systemic barriers to accessing CMS 

programs that hinder quality of care for 

beneficiaries and consumers. Consistent 

with Executive Order (E.O.) 13985, 

Advancing Racial Equity and Support 

for Underserved Communities through 

the Federal Government,1 the 

Committee will seek to advise and make 

recommendations to CMS on ensuring 

all eligible individuals can access CMS 

programs and identify how CMS can 

deliver benefits equitably to all people 

enrolled in CMS programs. The 

Committee will also serve as a dedicated 

platform for CMS collaboration with key 

interested persons to advance health 

equity by identifying how CMS can 

promote quality and access for 


ddrumheller on DSK120RN23PROD with NOTICES1